Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

Abstract: The present disclosure provides a gearbox and a vehicle, and relates to the field of vehicles technologies. The gearbox includes an output shaft and two drive assemblies, wherein each of the two drive assemblies is used to drive the output shaft; the drive assembly includes an electric machine, a reduction gear set, and a gear transmission assembly in transmission connection with the output shaft, and the electric machine is in transmission connection with the gear transmission assembly through the reduction gear set; the gear transmission assembly includes at least three gear pairs, and transmission ratios of respective gear pairs in the at least three gear pairs are different; and in response to the gearbox being in a first transmission mode, the reduction gear set is in transmission connection with the output shaft through one of the at least three gear pairs.

Abstract: The present invention pertains to the pharmaceutical field, and particularly relates to a pharmaceutical combination comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL inhibitor and one or more anticancer reagents, and the use of the combination to treat a disease such as cancer, specifically acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or multiple myeloma (MM) resistant or insensitive to Bcl-2 inhibitors and/or carrying Bcl-2 mutation and/or TP53 mutation. The invention also relates to a pharmaceutical composition or kit comprising the combination.

Abstract: An LNG gas supply system for a ship is provided, comprising an LNG storage tank, wherein: the LNG storage tank is connected with a BOG pipeline for outputting evaporated gas of natural gas, a low-pressure LNG treatment pipeline, a high-pressure LNG treatment pipeline and an ethylene glycol-water heating pipeline, wherein: the BOG pipeline includes a first regulating valve and a first-stage compressor unit arranged sequentially along a gas flow direction; the low-pressure LNG treatment pipeline includes a second regulating valve, a first cold source of a multi-stream vaporizer, and a separator arranged sequentially along the gas flow direction; the high-pressure LNG treatment pipeline includes a third regulating valve, a high-pressure booster pump and a second cold source of the multi-stream vaporizer arranged sequentially along the gas flow direction; and the ethylene glycol-water heating pipeline includes a medium storage tank for storing ethylene glycol water.

Abstract: An LNG gas supply system for a ship is provided, comprising an LNG storage tank, wherein: the LNG storage tank is connected with a BOG pipeline for outputting evaporated gas of natural gas, a low-pressure LNG treatment pipeline, a high-pressure LNG treatment pipeline and an ethylene glycol-water heating pipeline, wherein: the BOG pipeline includes a first regulating valve and a first-stage compressor unit arranged sequentially along a gas flow direction; the low-pressure LNG treatment pipeline includes a second regulating valve, a first cold source of a multi-stream vaporizer, and a separator arranged sequentially along the gas flow direction; the high-pressure LNG treatment pipeline includes a third regulating valve, a high-pressure booster pump and a second cold source of the multi-stream vaporizer arranged sequentially along the gas flow direction; and the ethylene glycol-water heating pipeline includes a medium storage tank for storing ethylene glycol water.

Abstract: Provided herein are pharmaceutical compositions comprising an MDM2 inhibitor and one or more anti-cancer agents for preventing and/or treating diseases, such as cancer. Methods for preventing and/or treating diseases, such as cancer, comprising administering to the patient in need thereof with the pharmaceutical compositions are also provided.

Abstract: The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.

Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

Abstract: The present disclosure relates to an electric drive axle, including a driving assembly, a power coupling gear, a first gear transmission assembly, a second gear transmission assembly and two half shafts connected by a differential, the driving assembly is used to drive the differential. In the above way, the electric drive axle and the electric vehicle realize 3 shifting speeds, and can timely engage in different speeds according to the vehicle load, road conditions, transportation time requirements, etc., so as to realize the efficient operation of the vehicle, improve the operation efficiency, reduce energy consumption, meet the power demand of commercial vehicles with diverse loads and working conditions, and obtain high transportation efficiency and economic benefits.

Abstract: The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.

Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Abstract: Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Abstract: The present disclosure discloses an electric drive axle, comprising a driving assembly, a power coupling gear, a first gear transmission assembly, a second gear transmission assembly and two half shafts connected by a differential, the driving assembly is used to drive the differential. In the above way, the electric drive axle and the electric vehicle provided according to the present disclosure realize 3 shifting speeds, and can timely engage in different speeds according to the vehicle load, road conditions, transportation time requirements, etc., so as to realize the efficient operation of the vehicle, improve the operation efficiency, reduce energy consumption, meet the power demand of commercial vehicles with diverse loads and working conditions, and obtain high transportation efficiency and economic benefits.

Abstract: The present disclosure provides a power semiconductor device and a manufacturing method thereof. In order to provide a power semiconductor device with improved latch-up immunity but without increasing device power loss and costs, a hole current path in a fourth semiconductor region of a first conductivity type between a gate trench and a dummy gate trench is shortened by providing a first contact trench between two adjacent gate trenches, and providing a second contact trench between the gate trench and a dummy gate trench such that the width and depth of the second contact trench are respectively greater than those of the first contact trench. The effect of the hole current on the potential rise of the fourth semiconductor region of the first conductivity type is suppressed, thereby suppressing the latch-up effect, and enhancing the switching reliability.

Abstract: The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

Abstract: Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

Abstract: The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.